J R Kramer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8595286/publications.pdf

Version: 2024-02-01

101384 88477 5,688 81 36 70 citations h-index g-index papers 82 82 82 7051 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology, 2017, 153, 996-1005.e1.	0.6	680
2	Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 1828-1837.e2.	0.6	490
3	Increasing Prevalence of HCC and Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Gastroenterology, 2011, 140, 1182-1188.e1.	0.6	349
4	Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology, 2016, 64, 130-137.	3.6	319
5	Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus. JAMA - Journal of the American Medical Association, 2007, 297, 2010.	3.8	294
6	Utilization of Surveillance for Hepatocellular Carcinoma Among Hepatitis C Virus–Infected Veterans in the United States. Annals of Internal Medicine, 2011, 154, 85.	2.0	272
7	The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Alimentary Pharmacology and Therapeutics, 2008, 27, 274-282.	1.9	235
8	Longâ€Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology, 2020, 71, 44-55.	3.6	188
9	Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71, 808-819.	3.6	170
10	A New Laboratory-Based Algorithm to Predict Development of Hepatocellular Carcinoma in Patients With Hepatitis C and Cirrhosis. Gastroenterology, 2014, 146, 1249-1255.e1.	0.6	156
11	The Effect of HIV Coinfection on the Risk of Cirrhosis and Hepatocellular Carcinoma in U.S. Veterans with Hepatitis C. American Journal of Gastroenterology, 2005, 100, 56-63.	0.2	148
12	Trends in the Burden of Nonalcoholic Fatty Liver Disease inÂaÂUnited States Cohort of Veterans. Clinical Gastroenterology and Hepatology, 2016, 14, 301-308.e2.	2.4	136
13	The Quality of Care Provided to Patients With Cirrhosis and Ascites in the Department of Veterans Affairs. Gastroenterology, 2012, 143, 70-77.	0.6	133
14	Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut, 2016, 65, 1252-1260.	6.1	113
15	Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting. American Journal of Gastroenterology, 2015, 110, 10-14.	0.2	110
16	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
17	The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut, 2018, 67, 553-561.	6.1	101
18	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. Journal of Hepatology, 2019, 70, 639-647.	1.8	101

#	Article	IF	CITATIONS
19	Gaps in the achievement of effectiveness of HCV treatment in national VA practice. Journal of Hepatology, 2012, 56, 320-325.	1.8	86
20	Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in HCV-Infected Veterans. American Journal of Gastroenterology, 2014, 109, 1427-1435.	0.2	84
21	Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. Journal of Hepatology, 2020, 73, 1425-1433.	1.8	81
22	Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology, 2013, 58, 538-545.	3.6	75
23	Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia. Digestive Diseases and Sciences, 2016, 61, 1714-1720.	1.1	72
24	Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. American Journal of Gastroenterology, 2011, 106, 483-491.	0.2	71
25	Circulating Inflammatory Cytokines and Adipokines Are Associated With Increased Risk of Barrett's Esophagus: A Case–Control Study. Clinical Gastroenterology and Hepatology, 2014, 12, 229-238.e3.	2.4	71
26	Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology, 2022, 75, 1420-1428.	3.6	65
27	Association between Helicobacter pylori and Barrett's Esophagus: A Case–Control Study. American Journal of Gastroenterology, 2014, 109, 357-368.	0.2	63
28	Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clinical Gastroenterology and Hepatology, 2018, 16, 1677-1678.	2.4	63
29	Barriers to hepatitis C treatment in the era of directâ€acting antiâ€viral agents. Alimentary Pharmacology and Therapeutics, 2017, 46, 992-1000.	1.9	62
30	Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clinical Infectious Diseases, 2016, 63, 291-299.	2.9	60
31	Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology, $2011, 53, 42-52$.	3.6	49
32	Dietary Nutrients Involved in One-Carbon Metabolism and Colonic Mucosa-Associated Gut Microbiome in Individuals with an Endoscopically Normal Colon. Nutrients, 2019, 11, 613.	1.7	48
33	The Effect of HIV Viral Control on the Incidence of Hepatocellular Carcinoma in Veterans With Hepatitis C and HIV Coinfection. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 456-462.	0.9	47
34	The effects of sustained virological response to directâ€acting antiâ€viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Alimentary Pharmacology and Therapeutics, 2019, 49, 1442-1447.	1.9	47
35	Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology, 2020, 72, 1242-1252.	3.6	47
36	Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Network Open, 2020, 3, e2023780.	2.8	45

#	Article	IF	CITATIONS
37	Oropharyngeal squamous cell carcinoma in the veteran population: Association with traditional carcinogen exposure and poor clinical outcomes. Head and Neck, 2015, 37, 1246-1253.	0.9	40
38	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine, 2021, 181, 949.	2.6	35
39	Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Alimentary Pharmacology and Therapeutics, 2014, 40, 949-954.	1.9	31
40	Realâ€world effectiveness of elbasvir/grazoprevir In <scp>HCV</scp> â€infected patients in the <scp>US</scp> veterans affairs healthcare system. Journal of Viral Hepatitis, 2018, 25, 1270-1279.	1.0	30
41	Accurate Identification of Fatty Liver Disease in Data Warehouse Utilizing Natural Language Processing. Digestive Diseases and Sciences, 2017, 62, 2713-2718.	1.1	28
42	Depression and Anxiety Are Common Among Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2022, 20, 194-203.e1.	2.4	23
43	Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large veterans administration medical centre. Alimentary Pharmacology and Therapeutics, 2008, 28, 1078-1087.	1.9	21
44	Validation of <scp>HIV</scp> â€infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Medicine, 2019, 20, 567-570.	1.0	19
45	Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists. Digestive Diseases and Sciences, 2018, 63, 1551-1557.	1.1	18
46	Incidence of AIDS-Related Kaposi Sarcoma in All 50 United States From 2000 to 2014. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 387-394.	0.9	18
47	The Performance of Process Measures in Hepatitis C. American Journal of Gastroenterology, 2012, 107, 1512-1521.	0.2	17
48	Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response. Clinical Gastroenterology and Hepatology, 2012, 10, 1270-1277.e3.	2.4	16
49	Risk and Predictors of Esophageal and Stomach Cancers in HIV-Infected Veterans: A Matched Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e65-e72.	0.9	15
50	Use and Yield of Endoscopy in Patients With Uncomplicated Gastroesophageal Reflux Disorder. JAMA Internal Medicine, 2014, 174, 462.	2.6	14
51	Prognostic Significance of p16 Cellular Localization in Oropharyngeal Squamous Cell Carcinoma. Annals of Clinical and Laboratory Science, 2016, 46, 132-9.	0.2	14
52	National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. Head and Neck, 2021, 43, 108-115.	0.9	12
53	Validity of code based algorithms to identify primary open angle glaucoma (POAG) in Veterans Affairs (VA) administrative databases. Ophthalmic Epidemiology, 2018, 25, 162-168.	0.8	11
54	Renal Trajectory Patterns Are Associated With Postdischarge Mortality in Patients With Cirrhosis and Acute Kidney Injury. Clinical Gastroenterology and Hepatology, 2020, 18, 1858-1866.e6.	2.4	11

#	Article	IF	Citations
55	Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Research, 2020, 174, 104698.	1.9	10
56	Spatial Characteristics of Colonic Mucosa-Associated Gut Microbiota in Humans. Microbial Ecology, $2021, 1.$	1.4	10
57	Physical activity and the risk of Barrett's esophagus. Ecological Management and Restoration, 2016, 29, 248-254.	0.2	8
58	The Validity of HCC Diagnosis Codes in Chronic Hepatitis B Patients in the Veterans Health Administration. Digestive Diseases and Sciences, 2017, 62, 1180-1185.	1.1	8
59	A Randomized Trial of Offâ€Site Collaborative Care for Depression in Chronic Hepatitis C Virus. Health Services Research, 2018, 53, 2547-2566.	1.0	8
60	Incidence and survival for oropharynx and nonâ€oropharynx head and neck cancers among veterans living with HIV. Cancer Medicine, 2020, 9, 9326-9335.	1.3	8
61	Hepatitis C virusâ€related complications are increasing in women veterans: A national cohort study. Journal of Viral Hepatitis, 2017, 24, 955-965.	1.0	7
62	Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection. Digestive Diseases and Sciences, 2014, 59, 273-281.	1.1	4
63	Determining Best Practices for Management of Bacteriuria in Spinal Cord Injury: Protocol for a Mixed-Methods Study. JMIR Research Protocols, 2019, 8, e12272.	0.5	4
64	4 - Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer (HCC) in Non-Alcoholic Fatty Liver Disease (NAFLD). Gastroenterology, 2018, 154, S-1.	0.6	3
65	Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection. Infectious Diseases and Therapy, 2020, 9, 355-365.	1.8	3
66	Veteran Women Living With Human Immunodeficiency Virus Have Increased Risk of Human Papillomavirus (HPV)-Associated Genital Tract Cancers. Clinical Infectious Diseases, 2021, 72, e359-e366.	2.9	3
67	Gout and open-angle glaucoma risk in a veteran population. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3371-3379.	1.0	2
68	Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure― Journal of Hepatology, 2019, 71, 638-639.	1.8	1
69	Effect of Body Weight and Other Metabolic Factors on Risk of Non-Small Cell Lung Cancer among Veterans with HIV and a History of Smoking. Cancers, 2020, 12, 3809.	1.7	1
70	The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study. BMC Cancer, 2021, 21, 776.	1.1	1
71	Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. American Journal of Drug and Alcohol Abuse, 2022, , 1-9.	1.1	1
72	Commentary: monitoring for myelosuppression in IBD - authors' reply. Alimentary Pharmacology and Therapeutics, 2013, 37, 155-155.	1.9	0

#	Article	IF	Citations
73	Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clinical Gastroenterology and Hepatology, 2017, 15, 137-139.	2.4	0
74	Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?― Journal of Hepatology, 2019, 70, 1301-1302.	1.8	0
75	Abstract 870: Immunogenetic determinants of head and neck cancer in Veterans in the Million Veteran Program cohort. , 2021, , .		0
76	Inflammatory biomarkers in HIV-infected veterans with non-small cell lung cancer receiving anti–PD-1 immunotherapy Journal of Clinical Oncology, 2018, 36, e21110-e21110.	0.8	0
77	Trends in gender-based disparity in incidence, mortality and survival for major digestive disease cancers in the U.S. (2000-2016) Journal of Clinical Oncology, 2020, 38, e13621-e13621.	0.8	0
78	92. Successful Scale-up of an Intervention to Decrease Unnecessary Urine Cultures Led to Improvements in Antibiotic Use. Open Forum Infectious Diseases, 2020, 7, S177-S177.	0.4	0
79	73. Identification of Novel Factors Associated with Inappropriate Treatment of Asymptomatic Bacteriuria Treatment in Acute and Long-term Care. Open Forum Infectious Diseases, 2021, 8, S153-S154.	0.4	0
80	Identification of Novel Factors Associated with Inappropriate Treatment of Asymptomatic Bacteriuria in Acute and Long-term Care. American Journal of Infection Control, 2022, , .	1.1	0
81	Reply. Hepatology, 2022, 76, E50-E50.	3.6	0